Top pharma stories
MM&M’s most popular pharma stories of the year spanned features on industry leaders, notable people moves and coverage of topics like drug pricing and changing requirements for DTC ads.
Collaboration among payers and pharma companies is making a comeback, spurred by a renewed appetite for value-based contracting on medicines. And with a wave of extraordinarily high-priced, curative therapies right around the corner, the pace is about to pick way up. Learn more here.
A commercial featuring the list price of Johnson & Johnson blood thinner Xarelto, the first U.S. direct-to-consumer TV drug ad to disclose price, debuted. Find out more about this advertisement here.
Armed with a great depth of expertise from a diverse array of industries, including beauty, retail, apparel, big tech, and startups, chief digital officers are helping pharma transform.
Pfizer’s chief digital officer Lidia Fonseca shares more about her upbringing, what she studied and about her career path. Read about Fonseca here.
Culture warrior Sebastian Guth explains why his greatest disappointment proved the most important moment in his professional development. Read more here.
Bipolar disorder can feel like an out-of-control elevator, according to Allergan’s marketing campaign for bipolar treatment Vraylar, which uses patients’ descriptions of the disorder. Find out more about this campaign here.
Vertex Pharmaceuticals has named Reshma Kewalramani as president and CEO, effective April 1, 2020. Read about other people moves in the industry here.
A group of Allergan’s alumni at Evolus have launched a competitor to Botox, Jeuveau. Find out more about this launch here.
Eli Lilly explained the choices it made for its drug ads for diabetes treatment Trulicity. Find out why the drugmaker opted for directing consumers to a website and toll-free phone number for price information.